Introduction {#Sec1}
============

Lung cancer (LC) remains the leading cause of cancer death worldwide accounting for 14.1 million new cancer cases and 8.2 million deaths per year \[[@CR1], [@CR2]\]. Worldwide incidence appears to be variable but equally distributed with increasing trends among males and females \[[@CR1], [@CR2]\]. LC is stratified into two major subtypes, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the latter representing 85-90 % of all cases of LC \[[@CR3]\]. Response to current cytotoxic therapies has reached a plateau in terms of response rate and survival \[[@CR4], [@CR5]\]. The development of molecular profiling technologies to assess DNA, RNA, proteins and metabolites heralds a new era in the understanding of the molecular basis of non-small-cell lung carcinoma (NSCLC) leading to potential advances in management and treatment of lung cancer \[[@CR6]\]. Novel molecular markers in non small-cell lung cancer (NSCLC) also include DNA damage repair genes. The pathogenesis of NSCLC cancer is complex and influenced by multiple factors including: a) environment (i.e. exposure to carcinogens, smoking habit, diet); b) genetic and epigenetic changes (such as p53 and EGFR gene mutations); c) pulmonary and systemic inflammatory conditions (such as concurrent Chronic Obstructive Pulmonary disease) \[[@CR7]--[@CR17]\]. At cellular level, activation status of several kinases involved in cell proliferation, apoptosis and inflammation is central to establishment and development of carcinogenesis. For example, constitutive activation of MEK-ERK, PI3K-AKT and/or PI3K-AKT-NF-κβ pathways plays a key role in oncogenesis and strongly promotes LC invasiveness \[[@CR13]--[@CR17]\]. AKT activation is present in 51 % of NSCLC although AKT mutations are rare (\<1 %) \[[@CR18], [@CR19]\]. However, the role of MEK and PI3K pathways as prognostic and/or predictive markers for cancer remains controversial \[[@CR20]\]. Today, the MEK and AKT inhibitors combined with chemotherapy are very promising for the treatment of several human cancers, including NSCLC \[[@CR18], [@CR19]\].

Despite the introduction of diagnostic tools such as computed tomography (CT) scans, Positrion Emission Tomography (PET) scan and bronchoscopy, the early diagnosis of LC remains unsatisfactory \[[@CR20]\]. Circulating biochemical biomarkers such as carcinoembryonic antigen (CEA) TPA, CYFRA 21.1 etc. have a limited impact in early diagnosis whereas methylation-based assays may represent a more promising strategy for early detection and follow-up of NSCLC by means of a differential label-free proteomic analysis \[[@CR21]\]. Actually, cancer detection, diagnosis and staging may be further improved by molecular selection \[[@CR2], [@CR21]\]. As current early detection procedures and treatments are unsatisfactory in terms of impact on quality of life and overall survival novel biomarkers need to be identified. In this context, the emerging "-omics" approach represents an important tool in the detection and quantitation of novel key-proteins as putative biomarkers for LC \[[@CR3], [@CR22]\].

In this study, we collected lung tumour specimens from 8 NSCLC chemotherapy naive patients undergoing surgery as well as surrounding cancer-free lung tissues and: a) investigated activation status of ERK, AKT, IKBα and ΝF-κβ; b) defined novel specific biomarkers for NSCLC diagnosis by means of a differential label-free proteomic analysis. We found: a) activation of all tested proteins and b) 20 proteins differentially expressed between NSCLC and controls. Finally, we validated, by western blotting, the two most differentially expressed proteins, carbonic anhydrase I and II (CAI, CAII) isoforms.

Materials and methods {#Sec2}
=====================

Lung tissues sampling {#Sec3}
---------------------

NSCLC tumour tissue specimens and surrounding cancer-free tissue were collected from eight chemotherapy naïve patients who underwent thoracic surgery. Hystological analysis of tumour tissue specimens was conducted by pathologists at Monaldi Hospital of Naples and confirmed the diagnosis as follows: six adenocarcinoma and two adenosquamous carcinoma; surrounding cancer-free lung specimens showed evidence of airway remodeling and signs of mucociliary dysfunction and alveolar destruction consistent with diagnosis of Chronic Obstructive pulmonary diseases. Samples were immediately frozen at −80 °C. The study was approved by the local ethics committee and conducted in accordance with ethical principles stated in most recent version of the Declaration of Helsinki on the applicable guidelines for good clinical practices.

Protein extraction {#Sec4}
------------------

Lung tissues were homogenized in buffer containing 50 mM Tris--HCl, pH 7.5, 150 mM NaCl, 1 % \[v/v\] Triton X-100, 10 % \[v/v\] glycerol, 0.5 mM PMSF and complete mini protease inhibitor cocktail (Roche, Basel, Switzerland). Tissues were disrupted using a Dounce homogenizer and centrifuged at 16,000 g at 4 °C for 30 min. Protein concentrations were determined using Bradford's reagent (Biorad Laboratories, CA, USA).

Western blotting analysis {#Sec5}
-------------------------

Protein extracts (30 μg) from each of 8 NSCLC and cancer-free lung tissue were incubated in Laemmli buffer with DTT, resolved on SDS-PAGE and then transferred onto nitrocellulose membranes (GE Healthcare, TX, USA) by Mini trans-blot electrophoresis transfer as previously described (Bio-Rad Laboratories, CA, USA) \[[@CR23]\]. p-ERK1/2, ERK1/2, p-AMPK, AMPK, p-AKT, AKT, p-P38, P38, p-IKBα, IKBα antibodies were from Cell Signaling, Netherlands; NF-κβ antibody was from BD bioscience; CAI antibody was from Santa Cruz Biotechnology, MA, USA; CAII antibody was from Rockland, PA, USA; GAPDH and β-actin antibodies were from Sigma-Aldrich, MO, USA. Immunoblots were detected using the ECL-Advance Western Blotting Detection kit (GE Healthcare, TX, USA). Western blot images were scanned by PDquest 7.1 software (Bio-Rad Laboratories, CA, USA). Densitometric measurements were made with the Quantity One 4.5 tool (Bio-Rad Laboratories, CA, USA). Each experiment was performed at least three times in duplicate.

In-gel digestion {#Sec6}
----------------

Pooled protein extracts (100 μg) were obtained by mixing equal amounts of all 8 NSCLC samples as well as of corresponding controls. Both pooled protein samples were re-suspended in Laemmli buffer with 0.1 M DTT, incubated at 95 °C for 5 min and separated by SDS-PAGE. Molecular weight was estimated by using Precision Plus All Blue protein standards (Bio-Rad Laboratories, CA, USA). Protein electrophoretic patterns were then visualized using GelCode Blue Stain Reagent. Protein bands of interest were excised from gel lanes, crushed and washed first with acetonitrile (ACN) and then with 50 mM ammonium bicarbonate (AMBIC); enzymatic digestions were carried out as previously described \[[@CR24]\]. In summary, protein samples were reduced in 10 mM DTT for 45 min at 56 °C and alkylated in 55 mM iodoacetamide in 50 mM AMBIC for 30 min at RT in the dark. Subsequently, gel particles were washed with 50 mM AMBIC and ACN and rehydrated in a modified trypsin solution (10 ng/μl) (Sigma, MO, USA) in 50 mM AMBIC pH 8.5, at 4 °C for 2 h. After removal of enzymatic solution, an aliquot of buffer solution was added and incubated at 37 °C for 18 h. The supernatant was collected, while gel pieces were subjected to further extraction in ACN at 37 °C for 15 min. Peptides obtained from extraction were pooled, vacuum-dried and resuspended in 0.2 % HCOOH before MS analysis.

Mass spectrometry analysis {#Sec7}
--------------------------

Peptide mixtures were analyzed by LC-MS MS using the LC/MSD Trap XCT Ultra (Agilent Technologies, CA, USA) equipped with a 1100 HPLC system and a chip cube (Agilent Technologies, CA, USA) as previously described \[[@CR24]\]. Briefly, after loading, peptide mixture (8 μl in 0,2 % HCOOH) was pre-concentrated, washed at 4 μl/min in 40 nl enrichment column (Agilent Technologies chip) and separated on a RP-C18 column (75 μm × 43 mm) at a flow rate of 200 nl/min with a linear gradient of eluent B (2 % formic acid in acetonitryl) in eluent A (2 % formic acid) from 5 to 60 % in 60 min. Peptides were analyzed using data-dependent acquisition of MS scan (400--2000 m/z) followed by MS/MS scans of the three most abundant ions. Dynamic exclusion was used to acquire a more complete survey of the peptides. A permanent exclusion list of the most frequent peptide contaminants was included in the acquisition as previously described \[[@CR25]\].

Protein identification and quantitation {#Sec8}
---------------------------------------

MASCOT software (Matrix Science, London, UK) was used for protein database searching as previously reported \[[@CR26]\]. The searches were performed using the NCBI database and the following standard parameters: *Homo Sapiens*; one missed cleavage; carboxyamidomethylation of Cys, partial Met oxidation and putative modification of Gln to pyro-Glu, mass tolerance of 300 ppm on precursor ions, and 0.6 Da on the product ions. Individual ion scores \>43 indicate identity or extensive homology (*p* \< 0.05). For label-free quantitation, Mascot format text files were analyzed by Proteome Discoverer platform (version 1.3; Thermo Scientific, Bremen, Germany), interfaced with an in-house Mascot server (version 2.3, Matrix Science, London, UK). All peptides with FDR ≤ 0.01 and a peptide rank of 1 were included. Spectral counts (SpC) were used for estimating protein abundance and comparing the expression of the same protein between tumour and control tissues. SpC log Ratio (Rsc) and Normalized Spectral Abundance Factor (NSAF) were calculated as previously described \[[@CR23]\].

Statistical analysis {#Sec9}
--------------------

Data are expressed as means ± SD and median. The statistical significance was established at *p* \<0.05. Two groups were compared with 2-tailed unpaired Student *t*-test.

Results {#Sec10}
=======

ERK1/2 and AKT kinases are significantly more activated in NSCLC tissues {#Sec11}
------------------------------------------------------------------------

To analyze the expression profile of the most relevant proteins regulating cell survival proliferation and apoptosis in NSCLC, we evaluated the activation of MAPK, ERK1/2 and AKT kinases in LC tissue specimens. We demonstrated that p-ERK1/2 and p-AKT activation was statistically different between control cancer-free and NSCLC tissues; in fact, cancer specimens have a significantly higher expression of p-ERK1/2 and p-AKT compared to the control (*p* \< 0.05) (Fig. [1a](#Fig1){ref-type="fig"}, and b, respectively). Ιn particular, p-ERK1/2 over-activation is 1,8 fold and p-AKT over-activation is 1,3-fold higher in NSCLC than in cancer-free tissues.Fig. 1ERK1/2 and AKT kinases are significantly more activated in NSCLC than in control lung tissues. **a** One representative western blotting image and graphical representation of pixel quantization of p-ERK1/2 and relative total ERK1/2 of 8 lung tissue specimens. **b** One representative western blotting image and graphical representation of pixel quantization of p-AKT and relative total AKT of 8 lung tissue specimens. Each experiment was performed three times in duplicate.^\*^  *= p* \< 0.05 by *t*-test analysis. For other details see [materials and methods](#Sec2){ref-type="sec"}

NF-κβ and IKBa proteins are over expressed/activated in NSCLC tissues {#Sec12}
---------------------------------------------------------------------

We analyzed the expression of NF − κβ and p-IKBα, two proteins involved in the control of survival and inflammation and therefore potentially affected in cancer specimens. We found that NSCLC tissues have statistically higher expression of NF − κβ and IKBα compared to control cancer-free (Fig. [2a, b](#Fig2){ref-type="fig"}, respectively). Ιn particular, NF − κβ is over-expressed 2.2 fold while IKBα is 4-fold over-expressed in NSCLC respect to cancer-free tissues.Fig. 2NF − κβ and p-IKBα are significantly more expressed in NSCLC than in control lung tissues. **a** One representative western blotting image and graphical representation of pixel quantization of NF − κβ and relative total GAPDH of 8 lung tissue specimens. **b** One representative western blotting image and graphical representation of pixel quantization of p-IKBα and total IKBα in 8 lung tissue specimens. Each experiment was performed three times in duplicate.^\*^  *= p* \< 0.05 by *t*-test analysis. For other details see [materials and methods](#Sec2){ref-type="sec"}

Identification of differentially expressed proteins in NSCLC tissues {#Sec13}
--------------------------------------------------------------------

We analyzed the protein expression profile of NSCLC and control cancer-free tissues in order to search for potentially LC biomarkers. Pooled protein extracts from 8 NSCLC and those from adjacent cancer-free lung tissues were fractionated onto a 10 % SDS-PAGE. As shown in Fig. [3](#Fig3){ref-type="fig"}, electrophoretic patterns between NSCLC and control extracts differed mainly in the low MW gel region. Protein bands from both lanes were excised individually, in-gel digested with trypsin, and analyzed by LC--MS/MS. We identified 38 proteins (see Table [1](#Tab1){ref-type="table"}).Fig. 3Differential protein expression profile between pooled tumour and control samples from 8 NSCLS patients (6 with histotype of AC and 2 with histotype of ASC). Arrow indicates protein band associated to CAI and CAII isoforms identification. For other details see [materials and methods](#Sec2){ref-type="sec"}Table 1Identified proteins in control and NSCLC tissues by MS analysisProteinGeneGene IDMW^a^Mascot Score^b^Mascot Score^b^\[Peptide\]^c^\[Peptide\]^c^NSCLCControllactoferrin precursorLTF1208318880214946 \[15\]298 \[5\]transferrinTF3774785579310581 \[9\]940 \[15\]78 kDa glucose-regulated protein precursorHSPA51650723772402507 \[8\]503 \[8\]moesinMSN450525767892412 \[8\]396 \[7\]myeloperoxidase, isoform CRA_dMPO11961487976923331 \[6\]73 \[1\]protein disulfide-isomerase A4 precursorPDIA4475830473229191 \[3\]128 \[2\]glyceraldehyde-3-phosphate dehydrogenaseGAPDH3164536201581 \[9\]375 \[6\]annexin A2 isoform 2ANXA21864516738808975 \[16\]504 \[10\]annexin A1ANXA1450210138918587 \[8\]522 \[7\]L-lactate dehydrogenase A isoform 1LDHA503185736950391 \[7\]N. D.^d^aldolase AALDOA2861439706240 \[4\]65 \[1\]peroxiredoxin-1PRDX1450559122324158 \[3\]253 \[5\]Aldo-keto reductase family 1 member C4AKR1C430815363137442155 \[3\]N. D.^d^60S acidic ribosomal protein P0RPLP0450666734423133 \[2\]N. D.^d^Actin, betaACTB1635915842078103 \[2\]238 \[4\]alcohol dehydrogenase beta subunitADH1B17809840665N. D.^d^107 \[2\]cathepsin DCTSD15787920626511151 \[3\]131 \[2\]stomatinSTOM1471507731958112 \[2\]N. D.^d^apolipoprotein A-I, isoform CRA_bAPOA117782723454566 \[9\]1057 \[17\]ribosomal protein L7RPL7133528829907170 \[2\]75 \[1\]tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gammaYWHAG38076519728373169 \[2\]96 \[1\]tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide variantYWHAB620891042256348 \[1\]113 \[2\]triosephosphate isomerase 1TPI113606626894633 \[10\]394 \[6\]proteasome subunit alpha type-6PSMA6839407627838184 \[3\]65 \[1\]carbonic anhydrase 1CA1450251728909104 \[2\]482 \[8\]carbonic anhydrase 2CA21508038629215N. D.^d^237 \[4\]azurocidinAZU12897727093130 \[2\]N. D.^d^phosphoglycerate mutase 1PGAM145057532890091 \[2\]N. D.^d^enoyl-CoA hydrataseEHHADH192228731807107 \[2\]N. D.^d^profilin-1PFN1482689815216N. D.^d^103 \[2\]endoplasmic reticulum protein 29, isoform CRA_bERP2911961839829638102 \[2\]N. D.^d^pre-serum amyloid P componentAPCS33775825495337 \[5\]318 \[5\]peroxiredoxin-6PRDX613425469825011342 \[6\]299 \[5\]MHC class II antigenHLA-DRB11018508230525N. D.^d^183 \[3\]MHC class I antigenHLA-DQB32565687221947N. D.^d^150 \[3\]Rab5c-like proteinRAB5C50828523781101 \[2\]97 \[2\]proteasome subunit beta type-4PSMB42253846729242N. D.^d^211 \[3\]rho GDP-dissociation inhibitorARHGDIB5667639323031N. D.^d^122 \[2\]^a^Theoretical MW^b^Protein score assigned by Mascot software is derived from ion scores that are -10\*Log \[p\], where p is the probability that the observed match is a random event^c^Number of peptides matched^d^Not determined

In order to quantitatively compare the protein expression profiles of NSCLC and cancer-free lung tissues, MS/MS outputs were analyzed by the Protein Discoverer platform and submitted to label-free quantitation analysis. Table [2](#Tab2){ref-type="table"} contains the details of the label-free quantitation method based on spectral counting for protein abundance estimation. In addition to the Normalized Spectral Abundance Factor (NSAF) for each samples, it has been calculated the semi-quantitative parameter R~sc~, representing the log~2~ ratio between the protein expression level of control *vs* NSCLC lung tissues. This label-free procedure revealed 20 differentially expressed proteins with R~sc~ ≥ 1.50 or ≤ −1.50. In Table [2](#Tab2){ref-type="table"} such species are ranked from the highest R~sc~ value to the lowest. In particular, our analysis demonstrated that seven proteins with R~sc~ ≥ 1.50 are over-expressed in control, while 13 proteins R~sc~ ≤ −1.50 are over-expressed in NSCLC tissues.Table 2Spectral counting and protein ratios for differentially expressed proteinsProteinGeneNSAF^a^NSAF^a^R~sc~ ^b^NSCLCControlcarbonic anhydrase 2CA200,006933,10MHC class I antigenHLA-DQB00,01312,43alcohol dehydrogenase beta subunitADH1B00,003562,43carbonic anhydrase 1CA10,005590,01802,10profilin-1PFN100,005131,94MHC class II antigenHLA-DRB100,009311,94rho GDP-dissociation inhibitorARHGDIB00,003931,94aldolase AALDOA0,005910,000974-1,61ribosomal protein L7RPL70,008690,00143-1,61enoyl-CoA hydrataseEHHADH0,002500-1,97lactoferrin precursorLTF0,01240,00154-2,25proteasome subunit alpha type-6PSMA60,01740,00144-2,52Aldo-keto reductase family 1 member C4AKR1C40,005790-2,71stomatinSTOM0,006040-2,7160S acidic ribosomal protein P0RPLP00,008070-3,20phosphoglycerate mutase 1PGAM10,01070-3,20endoplasmic reticulum protein 29, isoform CRA_bERP290,008940-3,20myeloperoxidase, isoform CRA_dMPO0,01840,00076-3,48L-lactate dehydrogenase A isoform 1LDHA0,008590-3,57azurocidinAZU10,01610-3,86^a^Normalized Spectral Abundance Factor^b^R~sc~ is calculated according to semi-quantitative parameter proposed by Old \[[@CR42]\] and represents the log~2~ ratio between the protein expression level of control vs the protein expression level of NSCLC tissues. Proteins with R~sc~ ≥ 1,50 or ≤ -1,50 were considered differentially expressed

Validation of carbonic anhydrase I and II isoforms {#Sec14}
--------------------------------------------------

Among proteins identified by MS analysis, we considered and validated carbonic anhydrase I (CAI) and II (CAII) isoforms. In fact, the two isoforms were identified in an intense protein band (MW between 25 kDa and 37 kDa), present in control and almost absent in the NSCLC (Fig. [3](#Fig3){ref-type="fig"}, as indicated by arrow); they were then quantified by label-free quantitation analysis. This procedure confirmed the strong over-expression of CAI and CAII (R~sc~ = 2,10 and R~sc~ = 3,10, respectively) in the control compared to NSCLC tissues (see Table [2](#Tab2){ref-type="table"}). Western blotting analysis verified the significant under-expression of CAI and CAII proteins in NSCLC tissues compared to the control (Fig. [4a, b](#Fig4){ref-type="fig"}).Fig. 4Western blot analysis confirms CAI and CAII as the two most differentially expressed proteins in NSCLC compared to control tissues. One representative western blot image (**a**) and graphical representation of pixel quantization (**b**) of CAI and CAII in lung tissues from 3 NSCLC patients (3 with histotype of AC and 1 with histotype of ASC). Each experiment was performed three times in duplicate^\*^  *= p* \< 0.05 by *t*-test analysis. For other details see [materials and methods](#Sec2){ref-type="sec"}

Discussion {#Sec15}
==========

Surgical resection, when indicated, remains the best treatment option for LC patient whilst radiotherapy and chemotherapy, although effective, have plateaued in terms of response and survival \[[@CR18], [@CR19]\]. This highlights the necessity for earlier diagnosis and more specific therapies to be found. We focused on NSCLC, the most common LC subtype, investigating: a) the activation/expression status of some protein factors potentially involved in LC development, progression and therapy, and b) the differentially expressed lung proteins between NSCLC and cancer-free tissues in order to define novel biomarkers for NSCLC.

Our data confirmed that ERK1/2, AKT, IKBα and NF-κβ are proteins activated and/or over-expressed in NSCLC. RAS--ERK has, until now, been one of the most extensively studied signaling pathways as ERK1/2 pathway being often up‐regulated in different human tumors and therefore represents an attractive target for the development of anticancer drugs. Although the activation status of ERK1/2 has been largely studied in various cell lines, few previous reports have demonstrated an aberrant activation of ERK1/2 in human tumors especially in that of lung \[[@CR27], [@CR28]\]. In this study, we identified an over-phosphorylation of ERK1/2 in NSCLC confirming this kinase as a key molecular component implicated also in NSCLC cancer.

PI3K/AKT kinase pathway is another central regulator of cell metabolism, proliferation, and survival \[[@CR29]--[@CR33]\]. Furthermore, AKT is activated in pre-neoplastic and neoplastic lesions and has been linked to ineffectiveness of therapies resulting in poor prognosis \[[@CR29], [@CR30]\]. In particular, activation of PI3K/AKT pathway in NSCLC has been associated with increased cellular survival and resistance to chemotherapy and radiation, two important clinical problems encountered in several cancers \[[@CR29]\]. Our data showed an over-activation of AKT in NSCLC cancer specimens. We analyzed not only AKT, but also the expression of IKBα and NF-kβ, other components connected to the PI3K/AKT pathway and involved in the control of survival and inflammation. The over-activation/expression of these molecules strongly supports that ERK1/2 and AKT pathways as well as IKBα/NF-κβ axis to be potential biomarkers for diagnosis/prognosis as well as development of novel targeted drugs in NSCLC. On the other hand, inactivation of NF-κβ, in combination with chemotherapeutic agents, leads to better therapeutic effects in several cancers \[[@CR31], [@CR32]\].

Our investigation also focused on the search for novel putative LC biomarkers. Proteomics in cancer research is a technology, by simultaneously examining thousands of proteins, can lead to the discovery of novel biomarkers for cancer \[[@CR33]\]. We analyzed and compared the protein expression profile obtained from NSCLC and adjacent cancer-free lung tissues and, through a label-free proteomic approach, defined a set of 20 differentially expressed proteins: seven under-expressed and 13 over-expressed in NSCLC respect to control tissues. To our knowledge, some of them have been previously correlated to LC: aldolase A (ALDOA), phosphoglycerate mutase 1 (PGAM1), l-lactate dehydrogenase A isoform 1 (LDHA), enoyl-CoA hydratase (HADHA), and stomatin (STOM) \[[@CR33]--[@CR37]\]. Here we report the first experimental evidence of a significant increase of the above mentioned proteins in tissues from NSCLC patients. ALDOA, in fact, has been identified as a differentially expressed protein in the bronchoalveolar lavage of patients with LC and/or COPD \[[@CR33]\]. Our data of PGAM1 over-expression agrees with that previously found in SCLC and adenocarcinomas (AC) \[[@CR36]\]. In addition, LDHA over-expression supports recent findings from NSCLC mouse models both providing a translational impact to murine data and demonstrating the key role of LDHA in LC onset and progression \[[@CR37]\]. Regarding the over-expression of HADHA protein, a significant positive correlation between HADHA expression and LC tumor was observed both in cisplatin-resistant LC cells and bioptic specimens from chemotherapy-resistant patients affected by NSCLC, or SCLC or AC has been reported \[[@CR34]\]. As for STOM, our observation is in contrast with the only other report describing STOM role in carcinogenesis showing an under-expression of STOM protein n NSCLC tissues with positive lymph node metastasis \[[@CR35]\].

The two most under-expressed proteins in NSCLC tissues, CAI and CAII, belong to a widespread family of 16 metallo-isoenzymes that catalyze the interconversion between carbon dioxide and the bicarbonate ion; these enzymes are involved in crucial physiological processes connected to respiration and transport of CO~2~/bicarbonate, in pH and CO~2~ homeostasis, and in many other metabolic reactions \[[@CR38]\]. Furthermore, reduction of CAs levels causes CO~2~ intracellular retention with consequent increased acidification of extracellular pH, a typical condition observed in rapidly growing tumors \[[@CR39], [@CR40]\].

Recently, a differential expression of CA isoenzymes has been reported in some malignant tumors, and in particular CAIX has been shown to be prognostic indicator and a potentially important biomarker in the evaluation of cancer \[[@CR39]--[@CR41]\]. CAIX is constitutively up-regulated in several cancer types such as lung cancer, breast cancer etc. and therefore, IHC analysis of its expression represents a useful tool for cancer detection, diagnosis and staging in different tissues \[[@CR41]\]. CAI and CAII are significantly less expressed in colorectal tumors, rectal carcinomas and pancreatic tumors, but over-expressed in nervous system tumors \[[@CR40]\]. Recently, a critical role of CAII was reported on LC tumour growth, angiogenesis and survival \[[@CR41]\]. To our knowledge, only one study has reported reduction of CAI and CAII expression in LC hypothesizing their role in tumour cell motility, tumour growth and metastasis formation \[[@CR38]\]. Our data about CAI and CAII confirm and underline the role of these two isoforms in NSCLC and support a role for them for the first time as biomarkers for disease diagnosis and/or prognosis able to select patients for NSCLC therapy.

Conclusions {#Sec16}
===========

Much effort is being made in the improvement of cancer detection, diagnosis and therapy by identifying more specific molecular biomarkers. In this context, we investigated and confirmed the involvement of ERK1/2, AKT, IKBα and NF-κβ proteins in NSCLC. Our data supports a role for these proteins as targets for development of novel drugs in LC treatment. Specifically, selective inhibitors of these molecular pathways could have important clinical implications for LC treatment. Comparing protein expression profile between NSCLC and adjacent cancer-free lung tissue, through a label-free proteomic approach, we found 20 differentially expressed proteins; among these we considered and validated CAI and CAII isoforms, the two most under-expressed proteins in cancer tissues. Our data strongly supports a role for these isoenzymes in the diagnosis and/or prognosis of NSCLC disease.

Highlights {#Sec17}
----------

ERK1/2, AKT and IKBα/NF-κβ pathways are significantly over-activated in NSCLC tissues *vs* control \[*p* \< 0.05\].Proteomic analysis revealed 20 differently expressed proteins (7 under- and 13 over-expressed) between NSCLC and cancer-free lung tissues (≥1.50 R~sc~ ≤ −1.50).Carbonic anhydrase I and II isoforms are strongly over-expressed in NSCLC tissues *vs* control (*p* \< 0.05).
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